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==========

Heat shock protein 27 (Hsp27) is a protein chaperone whose expression is induced by cytotoxic chemotherapy, as well as other cell stressors such as hyperthermia, oxidative stress, and radiation, resulting in cytoprotection against these insults \[[1](#onco12239-bib-0001){ref-type="ref"}\], \[[2](#onco12239-bib-0002){ref-type="ref"}\]. Various malignancies, including pancreatic adenocarcinoma, overexpress Hsp27 \[3\]; furthermore, preclinical studies show that Hsp27 expression may play a role in the resistance of pancreatic cancer cell lines to gemcitabine \[[4](#onco12239-bib-0004){ref-type="ref"}\], \[[5](#onco12239-bib-0005){ref-type="ref"}\], \[[6](#onco12239-bib-0006){ref-type="ref"}\]. Thus, inhibiting Hsp27 activity represents a viable therapeutic strategy in this disease. Apatorsen, an antisense oligonucleotide designed to bind to Hsp27 mRNA and block its translation into functional protein, offers one such approach \[[7](#onco12239-bib-0007){ref-type="ref"}\].

On these bases, we performed a randomized phase II trial to compare the safety and efficacy of gemcitabine and nab‐paclitaxel in combination with either apatorsen or placebo in the first‐line setting for patients with metastatic pancreatic cancer. The planned sample size of 130 provided 80% power to detect a difference in median survival of 8.5 versus 13.4 months (hazard ratio \[HR\] for death, 0.634; 1‐sided a = 0.1).

###### Median PFS and OS stratified by heat shock protein 27 levels

![](onco12239-tbl-0001){#nlm-graphic-1}

Abbreviations: CI, confidence interval; Hsp27, heat shock protein 27; OS, overall survival; PFS, progression‐free survival.

Although the incidence of toxicities did not differ significantly between the two treatment arms (most common treatment‐related toxicities of all grades on both arms included fatigue, cytopenias, and gastrointestinal symptoms), the addition of apatorsen to chemotherapy did not produce any improvement in clinical outcomes in the intent‐to‐treat population. The objective response rate (ORR) was identical (18%) on both treatment arms, whereas patients on the apatorsen arm fared numerically worse in terms of both progression‐free survival (PFS) and overall survival (OS) when compared with patients on the placebo arm, although these differences were not statistically significant (median PFS, 2.7 vs. 3.8 months, respectively \[*p* = .92; HR 1.0\]; median OS, 5.3 vs. 6.9 months, respectively \[*p* = .62; HR 1.1\]). Notably, the survival outcomes for patients on both arms of this study were considerably inferior to those observed on the gemcitabine/nab‐paclitaxel arm from the phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study \[[8](#onco12239-bib-0008){ref-type="ref"}\], for unclear reasons.

The only subgroup for whom a potential benefit of apatorsen could be identified was those patients with high serum levels of Hsp27, a marker associated with a very poor prognosis overall (median PFS for patients with high baseline serum Hsp27 levels, 3.3 vs. 0.9 months for apatorsen vs. placebo, respectively \[HR 0.38\], median OS 3.3 vs. 1.0 months \[HR 0.59\]). However, the number of subjects who fit into this category was too small, representing only 14% of the entire study population, to draw any definitive conclusions.

In summary, the addition of apatorsen to a standard combination chemotherapy regimen in the first‐line setting did not result in improvement in survival or other clinically relevant endpoints in patients with metastatic pancreatic cancer. Although further studies of this agent in unselected patients do not appear to be indicated, the findings from this trial do hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.

Trial Information {#onco12239-sec-0006}
=================

DiseaseMetastatic pancreatic adenocarcinomaStage of Disease/TreatmentMetastatic/advancedPrior TherapyNoneType of Study -- 1Phase IIType of Study -- 2RandomizedPFS*p* = 0.92, HR: 1.0OS*p* = 0.62, HR: 1.1Primary EndpointOverall survivalSecondary EndpointProgression‐free survivalSecondary EndpointToxicityInvestigator\'s AnalysisFeasible, possibly effective in patients with high Hsp27 serum levels

Drug Information for Phase II Control {#onco12239-sec-0007}
=====================================

Drug 1 Generic/Working nameNab‐paclitaxelTrade nameAbraxaneCompany nameCelgeneDrug typeOtherDrug classMicrotubule‐targeting agentDose125 milligrams (mg) per square meter (m^2^)RouteIVSchedule of administrationPlacebo days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycleDrug 2 Generic/Working nameGemcitabineTrade nameGemzarCompany nameEli LillyDrug typeOtherDrug classAntimetaboliteDose1,000 mg/m^2^RouteIVSchedule of administrationPlacebo days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle

Drug Information for Phase II Experimental {#onco12239-sec-0008}
==========================================

Drug 1 Generic/Working nameApatorsenTrade nameNot applicableCompany nameOncoGenexDrug typeOtherDrug classAntisense oligonucleotideDose600 mg per flat doseRouteIVSchedule of administrationApatorsen days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycleDrug 2 Generic/Working nameNab‐paclitaxelTrade nameAbraxaneCompany nameCelgeneDrug typeOtherDrug classMicrotubule‐targeting agentDose125 mg/m^2^Schedule of administrationApatorsen days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle pfofDrug 3 Generic/Working nameGemcitabineTrade nameGemzarCompany nameEli LillyDrug typeOtherDrug classAntimetaboliteDose1,000 mg/m^2^RouteIVSchedule of administrationApatorsen 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle

Patient Characteristics for Phase II Control {#onco12239-sec-0009}
============================================

Number of Patients, Male38Number of Patients, Female28StageIVAgeMedian (range): 65.5 (47--83)Number of Prior Systemic TherapiesMedian (range): NonePerformance Status ECOG0 --- 321 --- 322 ---3 ---Unknown --- 2Cancer Types or Histologic SubtypesCA19‐9 levels ≤90 U/mL 11CA19‐9 levels \>90 U/mL 54CA19‐9 levels Unknown 1Hsp27 expression high 11Hsp27 expression low 47Hsp27 expression Unknown 8

Patient Characteristics for Phase II Experimental {#onco12239-sec-0010}
=================================================

Number of Patients, Male37Number of Patients, Female29StageIVAgeMedian (range): 66.5 (39--82)Number of Prior Systemic TherapiesMedian (range): NonePerformance Status: ECOG0 --- 301 --- 362 ---3 ---Unknown ---Cancer Types or Histologic SubtypesCA19‐9 levels ≤90 U/mL 18CA19‐9 levels \>90 U/mL 47CA19‐9 levels unknown 1Hsp27 expression high 7Hsp27 expression low 55Hsp27 expression unknown 4

Primary Assessment Method for Phase II Control {#onco12239-sec-0011}
==============================================

Assessment: Total Patient Population: Overall Survival Number of patients screened66Number of patients enrolled66Number of patients evaluable for toxicity63Number of patients evaluated for efficacy66Evaluation methodRECIST 1.1Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 12 (18%)Response assessment SD*n* = 21 (32%)Response assessment PD*n* = 18 (28%)Response assessment OTHER*n* = 15 (22%)(Median) duration assessments PFS3.8 months(Median) duration assessments OS6.9 monthsKaplan‐Meier time unitsmonths
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Waterfall plot demonstrating best objective response in response‐evaluable subjects on control arm.image
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Assessment: Total Patient Population: Progression‐Free Survival {#onco12239-sec-0012}
===============================================================

Number of patients screened66Number of patients enrolled66Number of patients evaluable for toxicity63Number of patients evaluated for efficacy66Evaluation methodRECIST 1.1Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 12 (18%)Response assessment SD*n* = 21 (32%)Response assessment PD*n* = 18 (28%)Response assessment OTHER*n* = 15 (22%)(Median) duration assessments PFS3.8 months(Median) duration assessments OS6.9 monthsKaplan‐Meier time unitsmonths
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Primary Assessment Method for Phase II Experimental {#onco12239-sec-0013}
===================================================

Assessment: Total Patient Population: Overall Survival Number of patients screened66Number of patients enrolled66Number of patients evaluable for toxicity64Number of patients evaluated for efficacy66Evaluation methodRECIST 1.1Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 12 (18%)Response assessment SD*n* = 16 (24%)Response assessment PD*n* = 21 (32%)Response assessment OTHER*n* = 17 (26%)(Median) duration assessments PFS2.7 months(Median) duration assessments OS5.3Kaplan-Meier time unitsmonths
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Waterfall plot demonstrating best objective response in response‐evaluable subjects on experimental arm.image
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Assessment: Total Patient Population: Progression‐Free Survival {#onco12239-sec-0014}
===============================================================

Number of patients screened66Number of patients enrolled66Number of patients evaluable for toxicity64Number of patients evaluated for efficacy66Evaluation methodRECIST 1.1Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 12 (18%)Response assessment SD*n* = 16 (24%)Response assessment PD*n* = 21 (32%)Response assessment OTHER*n* = 17 (26%)Kaplan-Meier time unitsmonths
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Adverse Events {#onco12239-sec-1014}
==============
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Assessment, Analysis, and Discussion {#onco12239-sec-0015}
====================================

CompletionStudy completedPharmacokinetics/PharmacodynamicsCorrelative endpoints not metInvestigator\'s AssessmentFeasible, possibly effective in patients with high Hsp27 serum levels
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Pancreatic adenocarcinoma is expected to rise to the second leading cause of cancer‐related mortality in the U.S. by the end of this decade \[[9](#onco12239-bib-0009){ref-type="ref"}\]. Systemic therapy represents the mainstay of treatment for patients with advanced or metastatic disease, for whom two combination chemotherapy regimens have emerged as front‐line standards of care: gemcitabine plus nab‐paclitaxel \[[8](#onco12239-bib-0008){ref-type="ref"}\], and FOLFIRINOX (5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin) \[[10](#onco12239-bib-0010){ref-type="ref"}\]. However, despite these recent improvements in available cytotoxic therapies, overall prognosis in this disease remains very poor; for example, in the phase III MPACT trial leading to the approval of nab‐paclitaxel for metastatic pancreatic cancer, the median survival for patients receiving the combination of gemcitabine plus nab‐paclitaxel was only 8.5 months, representing a statistically significant but relatively modest absolute improvement of 1.8 months when compared with single‐agent gemcitabine \[[8](#onco12239-bib-0008){ref-type="ref"}\]. Clearly, novel drugs with unique mechanisms of action warrant further exploration.

Molecularly targeted therapies that have been approved for use in clinical oncology include monoclonal antibodies and small molecule inhibitors, particularly tyrosine kinase inhibitors. Unfortunately, many potential therapeutic targets are not amenable to these specific pharmacologic approaches, highlighting the importance of developing alternative strategies, including agents that can disrupt these targets at the gene expression level. Antisense oligonucleotides (ASOs), which are chemically modified stretches of single‐strand DNA complementary to the mRNA regions of a target gene that inhibit translation by forming RNA/DNA duplexes, represent one such approach to specifically prevent translation of functionally relevant genes.

Apatorsen, a 2'‐methoxyethyl oligonucleotide with phosphorothiolated internucleotide linkages, is designed to bind to heat shock protein 27 (Hsp27) mRNA and prevent translation into a functional protein. Targeting this specific heat shock protein represents an attractive therapeutic option, because Hsp27 can potentially affect multiple pathways implicated in cancer progression and resistance, as opposed to targeting a single pathway, a strategy that might have limited benefits in the face of the redundant signaling pathways and significant tumor heterogeneity. For example, overexpression of Hsp27 in cancer cells is induced by cytotoxic chemotherapy, as well as other cell stressors including hyperthermia, oxidative stress, and radiation, resulting in cytoprotection against these insults \[[1](#onco12239-bib-0001){ref-type="ref"}\], \[[2](#onco12239-bib-0002){ref-type="ref"}\]. Furthermore, Hsp27 serves to stabilize mutated or inappropriately activated oncoproteins that contribute to the initiation, growth, and metastasis of human cancers \[[2](#onco12239-bib-0002){ref-type="ref"}\], \[[11](#onco12239-bib-0011){ref-type="ref"}\].

The phase I dose‐escalation study of apatorsen in patients with castration‐resistant prostate cancer and other advanced cancers showed evidence of monotherapy activity as demonstrated by decline in tumor markers and circulating tumor cells, as well as stable measurable disease in 12 of 42 patients \[[12](#onco12239-bib-0012){ref-type="ref"}\]. Further evaluation of apatorsen has been pursued in combination with chemotherapeutic agents in clinical trials specific to non‐small cell lung and bladder cancer \[[13](#onco12239-bib-0013){ref-type="ref"}\], \[[14](#onco12239-bib-0014){ref-type="ref"}\].

Pancreatic adenocarcinomas show higher levels of Hsp27 expression when compared with healthy pancreatic tissue, and the protein can also be detected with high sensitivity in the serum of patients with pancreatic cancer \[[3](#onco12239-bib-0003){ref-type="ref"}\]. Preclinical studies additionally show that Hsp27 expression may play a role in the resistance of pancreatic cancer cell lines to gemcitabine \[[4](#onco12239-bib-0004){ref-type="ref"}\], \[[5](#onco12239-bib-0005){ref-type="ref"}\], \[[6](#onco12239-bib-0006){ref-type="ref"}\]. On these bases, the current study was designed to compare the safety and efficacy of gemcitabine and nab‐paclitaxel in combination with either apatorsen or placebo in the first‐line setting for patients with metastatic pancreatic cancer. However, we did not observe any improvement in clinical outcomes in the intent‐to‐treat population in this trial; indeed, patients on the apatorsen arm fared numerically worse in terms of both PFS and OS when compared with patients on the placebo control arm, although these differences were not statistically significant. The only subgroup for whom a potential benefit of apatorsen could be identified was those patients with high serum levels of Hsp27, a marker that portended a very poor prognosis overall. However, the number of subjects who fit into this category was too small, representing only 14% of the entire study population, to draw any definitive conclusions. Further studies, either prospectively designed trials or retrospective analyses of available clinically annotated samples, will be required to assess whether Hsp27 truly represents an adverse prognostic marker in this disease.

Several additional points are worth noting. First, the clinical outcomes for patients on both arms of this study were considerably inferior to those observed on the gemcitabine plus nab‐paclitaxel arm from the phase III MPACT trial \[[8](#onco12239-bib-0008){ref-type="ref"}\], in which patients achieved a median OS and PFS of 8.5 and 5.5 months, respectively. It is unclear why subjects on the current study fared so poorly, given similar demographics to the MPACT study; nevertheless, it seems fairly unlikely that a benefit from apatorsen would somehow be unmasked even if patients had achieved outcomes that more similarly matched those of the MPACT trial. Furthermore, because this study did not mandate pretreatment collection of tumor specimens, putative tissue‐based predictive markers of apatorsen sensitivity could not be assessed, nor could the pharmacodynamic effects of this agent given the absence of requiring on‐treatment tumor biopsies. No consistent trend was identified on serial serum Hsp27 measurements in responders versus nonresponders (data not shown). This lack of robust correlative data represents a major limitation of our study and highlights one of the major ongoing challenges in pancreatic cancer trial design in general, especially when trying to confirm the putative mechanism of action of novel targeted agents.

In conclusion, the addition of apatorsen to a standard combination chemotherapy regimen in the first‐line setting did not result in improved survival or other clinically relevant endpoints in patients with metastatic pancreatic cancer. Further studies of this agent in unselected patients do not appear to be indicated, although the findings from this trial do hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation. If ASO technologies targeting this and other cancer‐related genes continue to be pursued in pancreatic cancer, they should ideally be evaluated in the context of trials that mandate serial collection of both tumor and blood samples to look for predictive markers and pharmacodynamic markers of response, notwithstanding the clinical and logistic hurdles these may present in this patient population.
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